Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Rare Disease Organizations Call on Congress to Preserve Orphan Drug Tax Credit
Rare Daily Staff A group of nearly 140 rare disease organizations has sent a letter to leaders of the Senate Finance Committee and the House… Continue Reading
FDA Approves New Treatment for Adults with Rare Cancer
Rare Daily Staff The U.S. Food and Drug Administration granted accelerated approval to Bayer Healthcare’s Aliqupa, a treatment for adults… Continue Reading
WuXi NextCODE Completes $240 Million Financing
Rare Daily Staff WuXi NextCODE, a contract genomics organization that is building a global platform for genomic data, said it completed a… Continue Reading
RARECast: Aligning Interests in Rare Disease Partnerships
  Partnering is essential to advancing rare disease therapies, but while researchers, drugmakers, and patient groups share a common desire… Continue Reading
Inotek Pharmaceuticals Enters Merger Agreement with Rocket Pharmaceuticals
Rare Daily Staff Inotek Pharmaceuticals, following the mid-stage clinical failure of its lead therapy, said it has entered into a definitive… Continue Reading
BridgeBio Pharma Raises $135 Million and Discloses Rare Disease Pipeline
Rare Daily Staff BridgeBio, which focuses on early-stage discovery and development of therapies for rare diseases, said it raised $135… Continue Reading
ProQR Spins Out Amylon Therapeutics as Rare CNS Disease Company
Rare Daily Staff The Netherlands-based ProQR Therapeutics said it has spun out Amylon Therapeutics as a privately-held company focused on… Continue Reading
be-a-guest-blogger

Follow us on Twitter